Health Condition 1: Q642- Congenital posterior urethral valves
Conditions
Interventions
Intervention1: oxybutynin: anticholinergic agent oxybutynin at a dose of 0.2 mg/kg in two divided doses -for minimum duration of 3 months, maximum upto 6 months
Control Intervention1: terazosin: alpha
Sponsors
Postgraduate Institute of Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Boys aged between three months to 12 years, who have undergone primary TUF of PUV 2. Post TUF MCU showing adequate fulguration 3. Baseline UDS abnormalities including increased voiding pressure, low bladder capacity, poor compliance with elevated leak point pressure, high PVR
Exclusion criteria
Exclusion criteria: 1. Patients who have undergone vesicostomy or upper tract diversion 2. Patients post primary TUF with post-operative MCU suggestive of incomplete fulguration 3. Patients with a normal baseline UDS 4. Patients not willing to participate in the study 5. Presence of other urethral anomalies along with PUV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. subjective improvement in lower urinary tract symptoms 2. Bladder thickness and PVR on ultrasound 3. urodynamic changesTimepoint: 1. after 3 months 2. after 6 to 9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| breakthrough UTIs changes in renal function tests Timepoint: 1. after 3 months 2. after 6 to 9 months | — |
Countries
India
Contacts
Public ContactPalak Singhai
PGIMER chandigarh
Outcome results
None listed